On Sept. 1, 2020, Amyris announced that it had successfully scaled up the commercial production of Cannabigerol (CBG) leveraging its industrial fermentation process capability. Amyris expected to deliver about one ton of high purity CBG through fermentation as an alternative to the traditional production method of extraction from the Cannabis sativa L. plant.

First commercial revenue from the sale of this molecule was anticipated in 2020 as an ingredient in applications that are excluded from Amyris’s current collaboration agreements.